Investment Rating - The report maintains a "Buy" rating for the company [1][10][11] Core Insights - The company achieved significant growth in operating cash flow in Q4, with a year-on-year increase of 167% [7] - Despite a decline in revenue and net profit for 2024, the company is expected to see a recovery in revenue growth in the chemical sector in H2 2024 [6][10] - The expansion of supporting equipment business has shown remarkable results, with a 91.7% increase in related revenue [7] Financial Performance Summary - In 2024, the company reported operating revenue of 6.13 billion yuan, a decrease of 1.9% year-on-year, and a net profit attributable to shareholders of 850 million yuan, down 15.9% [5][10] - Q4 2024 revenue was 1.43 billion yuan, down 11% year-on-year, with a net profit of 180 million yuan, down 31.8% [5][10] - The company plans to distribute a cash dividend of 1.06 yuan per share for the year, totaling 611 million yuan, which represents 72.04% of the net profit [5] Revenue and Profit Forecast - Projected revenues for 2025-2027 are 6.46 billion, 7.11 billion, and 8.01 billion yuan respectively, with corresponding net profits of 890 million, 960 million, and 1.03 billion yuan [10][11] - The expected growth rates for revenue are 5%, 10%, and 13% for the years 2025, 2026, and 2027 respectively [10] Valuation Metrics - The report indicates a projected P/E ratio of 11 for 2025, decreasing to 9 for 2027 [10][11] - The company maintains a stable ROE of 19% across the forecast period [10][11]